10 Biotech Stocks Dragged Down By Short Selling

Screen Criteria:

All of these Biotech stocks have seen significant levels of short selling during the last month.

Ranking of This List:

Contextuall.com tracks the performance of a wide variety of company characteristics. Based on performance data over the last month, the list below is currently ranked 5 out of 232 lists. In other words, the company characteristics described below have outperformed 97.84% of lists in Contextuall’s coverage universe.

Average Weekly Returns:

Average 1-Week Return of All Stocks Mentioned Below: 4.87%

Average 1-Month Return of All Stocks Mentioned Below: 17.14%

Analysis of List Alpha:

Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Week): 6 out of 10 (60.0%)

Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Month): 9 out of 10 (90.0%)

(List sorted by monthly performance, from best to worst)

1. Infinity Pharmaceuticals, Inc. (INFI): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Shares shorted currently at 2.74M vs. 2.10M shares shorted in the previous month (an increase in short interest representing 2.89% of total float).

2. Amicus Therapeutics, Inc. (FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Shares shorted currently at 2.80M vs. 2.18M shares shorted in the previous month (an increase in short interest representing 2.51% of total float).

3. VIVUS Inc. (VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Shares shorted currently at 20.13M vs. 17.63M shares shorted in the previous month (an increase in short interest representing 3.02% of total float).

4. Santarus, Inc. (SNTS): Engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. Shares shorted currently at 4.25M vs. 2.62M shares shorted in the previous month (an increase in short interest representing 3.82% of total float).

5. NuPathe, Inc. (PATH): Focuses on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. Shares shorted currently at 1.29M vs. 1.17M shares shorted in the previous month (an increase in short interest representing 1.01% of total float).

6. Arena Pharmaceuticals, Inc. (ARNA): Focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Shares shorted currently at 61.75M vs. 50.95M shares shorted in the previous month (an increase in short interest representing 5.0% of total float).

7. Savient Pharmaceuticals, Inc. (SVNT): Focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. Shares shorted currently at 18.38M vs. 17.05M shares shorted in the previous month (an increase in short interest representing 2.61% of total float).

8. Idenix Pharmaceuticals Inc. (IDIX): Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. Shares shorted currently at 13.06M vs. 12.08M shares shorted in the previous month (an increase in short interest representing 1.38% of total float).

9. PDL BioPharma, Inc. (PDLI): Engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. Shares shorted currently at 21.94M vs. 19.17M shares shorted in the previous month (an increase in short interest representing 2.17% of total float).

10. Insmed Incorporated (INSM): Focuses on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. Shares shorted currently at 933.16K vs. 564.46K shares shorted in the previous month (an increase in short interest representing 1.95% of total float).

Original post